Brian Lehmann
Last active: 9/15/2015

Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.

McCubrey JA, Sokolosky ML, Lehmann BD, Taylor JR, Navolanic PM, Chappell WH, Abrams SL, Stadelman KM, Wong EW, Misaghian N, Horn S, Bäsecke J, Libra M, Stivala F, Ligresti G, Tafuri A, Milella M, Zarzycki M, Dzugaj A, Chiarini F, Evangelisti C, Martelli AM, Terrian DM, Franklin RA, Steelman LS
Adv Enzyme Regul. 2008 48: 113-35

PMID: 18423407 · PMCID: PMC2583357 · DOI:10.1016/j.advenzreg.2008.02.006

MeSH Terms (21)

Antineoplastic Agents, Hormonal Antineoplastic Combined Chemotherapy Protocols Apoptosis Breast Neoplasms Cell Cycle Cell Transformation, Neoplastic Cellular Senescence Doxorubicin Drug Resistance, Neoplasm Extracellular Signal-Regulated MAP Kinases Female Humans Metabolic Networks and Pathways Phosphatidylinositol 3-Kinases Protein Kinases Proto-Oncogene Proteins c-akt PTEN Phosphohydrolase raf Kinases Signal Transduction TOR Serine-Threonine Kinases Tumor Cells, Cultured

Connections (1)

This publication is referenced by other Labnodes entities: